Update: 26.08.2025
Last week: 33 week 2025 (11.08.2025 - 17.08.2025)
Last full month: July 2025
| Time period | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | |||||||||
| WoW | 8 215 | 3.8% | 13.9% | -0.3 | 18 902 598 | 3.1% | 10.3% | -0.3 | 6.4% |
| MoM | 35 432 | -4.8% | 14.0% | 0.2 | 82 298 386 | -4.1% | 10.7% | 0.2 | -6.4% |
| YTD | 292 670 | 21.9% | 13.1% | 1.5 | 652 266 222 | 27.1% | 9.8% | 0.4 | 7.6% |
| MAT | 474 035 | 24.3% | 13.2% | 2.5 | 978 299 599 | 22.2% | 9.6% | 0.7 | 1.1% |
| BRAINMAX | |||||||||
| WoW | 2 072 | 4.5% | 100.0% | 0 | 7 312 127 | 5.5% | 100.0% | 0 | 4.5% |
| MoM | 8 367 | -9.6% | 100.0% | 0 | 28 979 330 | -8.5% | 100.0% | 0 | -9.6% |
| YTD | 76 809 | 96.3% | 100.0% | 0 | 265 750 656 | 92.3% | 100.0% | 0 | 96.3% |
| MAT | 120 340 | 99.1% | 100.0% | 0 | 414 310 605 | 94.2% | 100.0% | 0 | 99.1% |
| GOLDLINE PLUS | |||||||||
| WoW | 13 403 | 5.5% | 45.5% | 0.3 | 43 681 673 | 4.5% | 37.0% | 0.1 | 4.9% |
| MoM | 59 170 | -11.1% | 46.8% | 1.5 | 194 213 502 | -9.7% | 38.4% | 1.6 | -13.9% |
| YTD | 516 038 | -7.0% | 45.8% | 0.8 | 1 668 596 491 | -4.5% | 37.4% | 0.7 | -8.7% |
| MAT | 790 304 | -6.0% | 46.0% | 0.6 | 2 524 498 200 | -5.1% | 37.6% | -0.3 | -7.2% |
| MIGRENIUM | |||||||||
| WoW | 8 396 | 5.1% | 0.3% | 0 | 2 966 900 | 4.8% | 0.5% | 0 | 8.7% |
| MoM | 33 596 | -4.9% | 0.3% | 0 | 11 944 032 | -4.5% | 0.4% | -0.1 | 6.0% |
| YTD | 267 043 | -31.1% | 0.3% | -0.2 | 94 041 126 | -21.8% | 0.5% | -0.2 | 5.4% |
| MAT | 447 136 | -26.6% | 0.4% | -0.1 | 155 374 501 | -6.8% | 0.5% | -0.1 | 2.4% |
| MODELAX-N | |||||||||
| WoW | 23 983 | -1.4% | 18.0% | -1 | 13 474 316 | -1.3% | 13.3% | -1.5 | 0.8% |
| MoM | 109 558 | -17.1% | 18.9% | -4.5 | 61 104 818 | -14.6% | 13.7% | -3.1 | 2.8% |
| YTD | 926 218 | -3.5% | 20.1% | -2.7 | 496 106 560 | 19.8% | 14.5% | -0.2 | 9.7% |
| MAT | 1 429 988 | 1.6% | 20.0% | -1.2 | 741 175 272 | 30.0% | 14.1% | 1 | 7.8% |
| REDUXIN | |||||||||
| WoW | 9 322 | -0.8% | 31.6% | -1.8 | 51 079 035 | 0.1% | 43.2% | -1.8 | 4.9% |
| MoM | 39 941 | -15.6% | 31.6% | -0.6 | 216 342 541 | -16.7% | 42.8% | -1.6 | -13.9% |
| YTD | 356 966 | -12.1% | 31.7% | -1.2 | 1 946 374 435 | -10.3% | 43.7% | -2 | -8.7% |
| MAT | 546 528 | -8.8% | 31.8% | -0.6 | 2 939 995 999 | -6.0% | 43.8% | -0.7 | -7.2% |
| REDUXIN FORTE | |||||||||
| WoW | 3 161 | 8.5% | 10.7% | 0.4 | 15 272 678 | 12.5% | 12.9% | 0.9 | 4.9% |
| MoM | 13 181 | -11.7% | 10.4% | 0.3 | 61 917 260 | -8.5% | 12.2% | 0.7 | -13.9% |
| YTD | 113 721 | 4.1% | 10.1% | 1.2 | 520 786 672 | 10.2% | 11.7% | 1.7 | -8.7% |
| MAT | 171 841 | 3.6% | 10.0% | 1 | 769 776 168 | 8.7% | 11.5% | 1.4 | -7.2% |
| SALVISAR | |||||||||
| WoW | 10 186 | 16.2% | 1.4% | 0.1 | 5 517 976 | 16.2% | 1.4% | 0.1 | 9.5% |
| MoM | 37 734 | -12.3% | 1.3% | -0.1 | 20 254 565 | -11.7% | 1.3% | -0.1 | -3.9% |
| YTD | 387 903 | 18.1% | 1.6% | 0.3 | 195 788 569 | 46.2% | 1.6% | 0.4 | -2.6% |
| MAT | 631 252 | 25.2% | 1.7% | 0.4 | 302 809 552 | 57.3% | 1.6% | 0.5 | -4.5% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 292 670 | 21.9% | 13.1% | 1.5 | 652 266 222 | 27.1% | 9.8% | 0.4 | 7.6% |
| BRAINMAX | 76 809 | 96.3% | 100.0% | 0 | 265 750 656 | 92.3% | 100.0% | 0 | 96.3% |
| GOLDLINE PLUS | 516 038 | -7.0% | 45.8% | 0.8 | 1 668 596 491 | -4.5% | 37.4% | 0.7 | -8.7% |
| MIGRENIUM | 267 043 | -31.1% | 0.3% | -0.2 | 94 041 126 | -21.8% | 0.5% | -0.2 | 5.4% |
| MODELAX-N | 926 218 | -3.5% | 20.1% | -2.7 | 496 106 560 | 19.8% | 14.5% | -0.2 | 9.7% |
| REDUXIN CAPS | 356 966 | -12.1% | 31.7% | -1.2 | 1 946 374 435 | -10.3% | 43.7% | -2 | -8.7% |
| REDUXIN FORTE | 113 721 | 4.1% | 10.1% | 1.2 | 520 786 672 | 10.2% | 11.7% | 1.7 | -8.7% |
| SALVISAR | 387 903 | 18.1% | 1.6% | 0.3 | 195 788 569 | 46.2% | 1.6% | 0.4 | -2.6% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 474 035 | 24.3% | 13.2% | 2.5 | 978 299 599 | 22.2% | 9.6% | 0.7 | 1.1% |
| BRAINMAX | 120 340 | 99.1% | 100.0% | 0 | 414 310 605 | 94.2% | 100.0% | 0 | 99.1% |
| GOLDLINE PLUS | 790 304 | -6.0% | 46.0% | 0.6 | 2 524 498 200 | -5.1% | 37.6% | -0.3 | -7.2% |
| MIGRENIUM | 447 136 | -26.6% | 0.4% | -0.1 | 155 374 501 | -6.8% | 0.5% | -0.1 | 2.4% |
| MODELAX-N | 1 429 988 | 1.6% | 20.0% | -1.2 | 741 175 272 | 30.0% | 14.1% | 1 | 7.8% |
| REDUXIN CAPS | 546 528 | -8.8% | 31.8% | -0.6 | 2 939 995 999 | -6.0% | 43.8% | -0.7 | -7.2% |
| REDUXIN FORTE | 171 841 | 3.6% | 10.0% | 1 | 769 776 168 | 8.7% | 11.5% | 1.4 | -7.2% |
| SALVISAR | 631 252 | 25.2% | 1.7% | 0.4 | 302 809 552 | 57.3% | 1.6% | 0.5 | -4.5% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 8 215 | 3.8% | 13.9% | -0.3 | 18 902 598 | 3.1% | 10.3% | -0.3 | 6.4% |
| BRAINMAX | 2 072 | 4.5% | 100.0% | 0 | 7 312 127 | 5.5% | 100.0% | 0 | 4.5% |
| GOLDLINE PLUS | 13 403 | 5.5% | 45.5% | 0.3 | 43 681 673 | 4.5% | 37.0% | 0.1 | 4.9% |
| MIGRENIUM | 8 396 | 5.1% | 0.3% | 0 | 2 966 900 | 4.8% | 0.5% | 0 | 8.7% |
| MODELAX-N | 23 983 | -1.4% | 18.0% | -1 | 13 474 316 | -1.3% | 13.3% | -1.5 | 0.8% |
| REDUXIN CAPS | 9 322 | -0.8% | 31.6% | -1.8 | 51 079 035 | 0.1% | 43.2% | -1.8 | 4.9% |
| REDUXIN FORTE | 3 161 | 8.5% | 10.7% | 0.4 | 15 272 678 | 12.5% | 12.9% | 0.9 | 4.9% |
| SALVISAR | 10 186 | 16.2% | 1.4% | 0.1 | 5 517 976 | 16.2% | 1.4% | 0.1 | 9.5% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 35 432 | -4.8% | 14.0% | 0.2 | 82 298 386 | -4.1% | 10.7% | 0.2 | -6.4% |
| BRAINMAX | 8 367 | -9.6% | 100.0% | 0 | 28 979 330 | -8.5% | 100.0% | 0 | -9.6% |
| GOLDLINE PLUS | 59 170 | -11.1% | 46.8% | 1.5 | 194 213 502 | -9.7% | 38.4% | 1.6 | -13.9% |
| MIGRENIUM | 33 596 | -4.9% | 0.3% | 0 | 11 944 032 | -4.5% | 0.4% | -0.1 | 6.0% |
| MODELAX-N | 109 558 | -17.1% | 18.9% | -4.5 | 61 104 818 | -14.6% | 13.7% | -3.1 | 2.8% |
| REDUXIN CAPS | 39 941 | -15.6% | 31.6% | -0.6 | 216 342 541 | -16.7% | 42.8% | -1.6 | -13.9% |
| REDUXIN FORTE | 13 181 | -11.7% | 10.4% | 0.3 | 61 917 260 | -8.5% | 12.2% | 0.7 | -13.9% |
| SALVISAR | 37 734 | -12.3% | 1.3% | -0.1 | 20 254 565 | -11.7% | 1.3% | -0.1 | -3.9% |
ОБОЗНАЧЕНИЯ
WoW - Week Over Week - показатели для сравнения результатов текущей и предыдущей недели
MoM - Month Over Month - показатели для сравнения результатов последнего полного месяца и предыдущего полного месяца
YTD - Year to Date - показатели для сравнения результатов за период времени, начинающийся с первого дня текущего календарного года до текущей даты с результатами за сопоставимый период прошлого года
MAT - Moving Annual Total - показатели для сравнения результатов за период 12 месяцев, с датой окончания на последней доступной неделе, с результатами за сопоставимый период прошлого года
MS - Market Share - Доля рынка = (Продажи бренда / Продажи категории)*100%
Change, % = (Продажи бренда за последний период / Продажи бренда за предыдущий период - 1)*100%
Change, p.p. = Доля бренда на рынке за последний период - Доля бренда на рынке за предыдущий период (выражается в процентных пунктах)
Cat. Volume Change, % = (Продажи категории в упаковках за последний период / Продажи категории в упаковках за предыдущий период - 1)*100%
Каждая категория собрана специально для каждого бренда и включает в себя бренд и его конкурентов
Список конкурентов можно найти в разделе “MS of competitors” в блоке каждого бренда
ABBREVIATIONS
WoW - Week Over Week - indicators for comparing the results of the current and previous week
MoM - Month Over Month - indicators for comparing the results of the* last full month* and previous full month
YTD - Year to Date - indicators for comparing the results of the period of time beginning the first day of the current calendar year up to the current date with the results of the comparable period last year
MAT - Moving Annual Total - indicators for comparing the results of the period, being 12 month period ending on the last week with the results of the comparable period last year
MS - Market Share - (Brand Sales / Category Sales)*100%
Change, % = (Brand Sales of the last period / Brand Sales of the previous period - 1)*100%
Change, p.p. = Brand Market Share of the last period - Brand Market Share of the previous period (expressed in percentage points)
Cat. Volume Change, % = (Category Sales in packs of the last period / Category Sales in packs of the previous period - 1)*100%
Each category is created specifically for each brand and includes the brand and its competitors
The list of competitors can be found in the subsection “MS of competitors” in sections for each brand
## [1] "MODELAX-N"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #2"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #4"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #8"
## [1] "MODELAX-N"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #2"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #4"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #8"
## [1] "AMBENE BIO"
## [1] "AMBENE BIO SOL FOR INJ 1 ML #10"
## [1] "AMBENE BIO SOL FOR INJ 2 ML #5"
## [1] "AMBENE BIO"
## [1] "AMBENE BIO SOL FOR INJ 1 ML #10"
## [1] "AMBENE BIO SOL FOR INJ 2 ML #5"
## [1] "MIGRENIUM"
## [1] "MIGRENIUM COATED TABLETS 65 MG+500 MG #20"
## [1] "MIGRENIUM"
## [1] "MIGRENIUM COATED TABLETS 65 MG+500 MG #20"
## [1] "SALVISAR"
## [1] "SALVISAR UNGUENT FOR EXT USE 100 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #2"
## [1] "SALVISAR UNGUENT FOR EXT USE 50 G #1"
## [1] "SALVISAR"
## [1] "SALVISAR UNGUENT FOR EXT USE 100 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #2"
## [1] "SALVISAR UNGUENT FOR EXT USE 50 G #1"
## [1] "REDUXIN CAPS"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #10"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #30"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #30"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #60"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #90"
## [1] "REDUXIN CAPS"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #10"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #30"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #90"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #10"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #30"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #60"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #90"
## [1] "REDUXIN FORTE"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #30"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #60"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #90"
## [1] "REDUXIN FORTE"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #30"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #60"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #30"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #60"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #90"
## [1] "GOLDLINE PLUS"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #10"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #90"
## [1] "GOLDLINE PLUS"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #10"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #90"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #10"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #90"
## [1] "BRAINMAX"
## [1] "BRAINMAX CAPS 250 MG+250 MG #20"
## [1] "BRAINMAX CAPS 250 MG+250 MG #40"
## [1] "BRAINMAX CAPS 250 MG+250 MG #60"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 2,5 ML #10"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 5 ML #10"
## [1] "BRAINMAX"
## [1] "BRAINMAX CAPS 250 MG+250 MG #20"
## [1] "BRAINMAX CAPS 250 MG+250 MG #40"
## [1] "BRAINMAX CAPS 250 MG+250 MG #60"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 2,5 ML #10"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 5 ML #10"
[RUS] ОБОЗНАЧЕНИЯ
WoW - Week Over Week - показатели для сравнения результатов текущей и предыдущей недели
MoM - Month Over Month - показатели для сравнения результатов последнего полного месяца и предыдущего полного месяца
YTD - Year to Date - показатели для сравнения результатов за период времени, начинающийся с первого дня текущего календарного года до текущей даты с результатами за сопоставимый период прошлого года
MAT - Moving Annual Total - показатели для сравнения результатов за период 12 месяцев, с датой окончания на последней доступной неделе, с результатами за сопоставимый период прошлого года
MS - Market Share - Доля рынка = (Продажи бренда / Продажи категории)*100%
Change, % = (Продажи бренда за последний период / Продажи бренда за предыдущий период - 1)*100%
Change, p.p. = Доля бренда на рынке за последний период - Доля бренда на рынке за предыдущий период (выражается в процентных пунктах)
Cat. Volume Change, % = (Продажи категории в упаковках за последний период / Продажи категории в упаковках за предыдущий период - 1)*100%
Каждая категория собрана специально для каждого бренда и включает в себя бренд и его конкурентов
Список конкурентов можно найти в разделе “MS of competitors” в блоке каждого бренда
[ENG] ABBREVIATIONS
WoW - Week Over Week - indicators for comparing the results of the current and previous week
MoM - Month Over Month - indicators for comparing the results of the last full month and previous full month
YTD - Year to Date - indicators for comparing the results of the period of time beginning the first day of the current calendar year up to the current date with the results of the comparable period last year
MAT - Moving Annual Total - indicators for comparing the results of the period, being 12 month period ending on the last week with the results of the comparable period last year
MS - Market Share - (Brand Sales / Category Sales)*100%
Change, % = (Brand Sales of the last period / Brand Sales of the previous period - 1)*100%
Change, p.p. = Brand Market Share of the last period - Brand Market Share of the previous period (expressed in percentage points)
Cat. Volume Change, % = (Category Sales in packs of the last period / Category Sales in packs of the previous period - 1)*100%
Each category is created specifically for each brand and includes the brand and its competitors
The list of competitors can be found in the subsection “MS of competitors” in sections for each brand
DATA SOURCES:
DSM: Sales
Palomars: TRPs